Fondamentali CSCI
COSCIENS BIOPHARMA INC bilanci, compresi i ricavi, spese e i profitti
Il fatturato totale di CSCI per l'ultimo trimestre è di 2.55 M CAD, in calo del 20.19% rispetto al trimestre precedente. L'utile netto nel Q3 24 è di -7.85 M CAD.
Q4 '16
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−18,00 M
−12,00 M
−6,00 M
0,00
6,00 M
Fatturato totale
Utile lordo
Utile operativo
Utile lordo
Utile netto
Valuta: CAD
Q4 '16
Dic 2016
Q1 '17
Mar 2017
Q2 '17
Giu 2017
Q3 '17
Set 2017
Q4 '17
Dic 2017
Q1 '18
Mar 2018
Q2 '18
Giu 2018
Q3 '18
Set 2018
Q4 '18
Dic 2018
Q1 '19
Mar 2019
Q2 '19
Giu 2019
Q3 '19
Set 2019
Q4 '19
Dic 2019
Q1 '20
Mar 2020
Q2 '20
Giu 2020
Q3 '20
Set 2020
Q4 '20
Dic 2020
Q1 '21
Mar 2021
Q2 '21
Giu 2021
Q3 '21
Set 2021
Q4 '21
Dic 2021
Q1 '22
Mar 2022
Q2 '22
Giu 2022
Q3 '22
Set 2022
Q4 '22
Dic 2022
Q1 '23
Mar 2023
Q2 '23
Giu 2023
Q3 '23
Set 2023
Q4 '23
Dic 2023
Q1 '24
Mar 2024
Q2 '24
Giu 2024
Q3 '24
Set 2024
TTM
Fatturato totaleCrescita YoY
3,37 M
+179,94%
2,88 M
+49,79%
3,02 M
—
4,02 K
−99,83%
164,80 K
−95,12%
5,39 K
−99,81%
3,20 M
+6,00%
2,55 M
+63.322,78%
5,92 M
−111,32 K
−77,10 K
−245,78 K
−71,09 K
−133,48 K
−80,92 K
−2,08 M
−1,42 M
−3,71 M
Utile lordoCrescita YoY
3,26 M
+188,19%
2,80 M
+57,74%
2,77 M
—
−67,06 K
−102,83%
31,33 K
−99,04%
−75,52 K
−102,70%
1,12 M
−59,56%
1,13 M
—
2,21 M
−8,87 M
−8,49 M
−6,61 M
−6,04 M
−8,74 M
−8,16 M
−6,26 M
−7,73 M
−30,89 M
Utile operativoCrescita YoY
−5,60 M
−40,83%
−5,69 M
−51,82%
−3,83 M
+36,33%
−6,10 M
−25,57%
−8,71 M
−55,48%
−8,24 M
−44,81%
−5,14 M
−33,99%
−6,59 M
−8,04%
−28,68 M
−11,30 M
−64,92 K
452,61 K
543,21 K
1,04 M
482,80 K
2,54 M
−1,41 M
2,65 M
Utile lordoCrescita YoY
−16,90 M
−366,57%
−5,76 M
−72,11%
−3,38 M
+37,18%
−5,56 M
−24,46%
−7,67 M
+54,60%
−7,76 M
−34,79%
−2,59 M
+23,29%
−8,00 M
−43,94%
−26,03 M
−16,90 M
−5,76 M
−3,38 M
−5,56 M
−7,67 M
−7,76 M
−1,95 M
−7,85 M
−25,23 M
Utile nettoCrescita YoY
−16,90 M
−363,34%
−5,76 M
−72,11%
−3,38 M
+37,18%
−5,56 M
−24,46%
−7,67 M
+54,60%
−7,76 M
−34,79%
−1,95 M
+42,47%
−7,85 M
−41,19%
−25,23 M
−16,90 M
−5,76 M
−3,38 M
−5,56 M
−7,67 M
−7,76 M
−1,95 M
−7,85 M
−25,23 M
Utile per azione, base (EPS base)Crescita YoY
−13,92
−363,32%
−4,74
−72,08%
−2,79
+37,18%
−4,58
−24,46%
−6,32
+54,60%
−25,56
−439,15%
−0,88
+68,54%
−2,53
+44,82%
−35,28
Utile per azione, diluito (EPS diluito)Crescita YoY
−13,92
−363,32%
−4,74
−72,08%
−2,79
+37,18%
−4,58
−24,46%
−6,32
+54,60%
−25,56
−439,15%
−0,88
+68,54%
−2,53
+44,82%
−35,28
1,21 M
1,21 M
1,21 M
1,21 M
1,21 M
303,49 K
2,22 M
3,11 M
—
1,21 M
1,21 M
1,21 M
1,21 M
1,21 M
303,49 K
2,22 M
3,11 M
—
EBITDACrescita YoY
−5,56 M
−41,57%
−5,64 M
−52,23%
−3,78 M
+36,84%
−6,05 M
−25,52%
−8,65 M
−55,61%
−8,18 M
−45,15%
−4,62 M
−22,43%
−5,94 M
+1,76%
−27,40 M
EBITCrescita YoY
−5,60 M
−40,83%
−5,69 M
−51,82%
−3,83 M
+36,33%
−6,10 M
−25,57%
−8,71 M
−55,48%
−8,24 M
−44,81%
−5,14 M
−33,99%
−6,59 M
−8,04%
−28,68 M
−8,98 M
−8,57 M
−6,85 M
−6,11 M
−8,88 M
−8,25 M
−8,34 M
−9,15 M
−34,60 M